Biocept: Plus Therapeutics expands supply agreement with Biocept for cerebrospinal fluid tumour cell enumeration assay
Plus Therapeutics, Inc., a clinical─stage pharmaceutical company, announced it has expanded its supply agreement with Biocept by acquiring an option to exclusively license Biocept's CNSide, a CSF─based
Read full article »
Biocept is a California-based molecular diagnostics company that researches and develops molecular diagnostic assays for the treatment of cancer.
Read more